As Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.
Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.
Bayer AG is buying Vividion Therapeutics, a San Diego-based company that focuses on drug development using protein surface screening, in a $2 billion deal.
GlaxoSmithKline will lay out plans to boost the spending power of the company’s research-focused pharmaceuticals business at an investor day on June 23, as analysts call on the British drugmaker to boost drug development prospects with takeovers or alliances.
Drug development requires the coordinated efforts of a broad set of disciplines, including nonclinical, clinical, regulatory and commercial experts.
CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.
One of the more cynical attacks on our industry goes something like this: “Taxpayers fund medical research through research grants, so they should get the benefits of any discoveries, not the greedy pharma companies.” I’m sure you’ve heard it. Politicians and pundits of all stripes love to reinforce the idea that pharma is gorging at the public trough – that all we do is gobble up federal grants as seed money for our outrageously priced nostrums.
Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.
PerkinElmer Inc. expanded the company’s presence in cell biology with the $260 million acquisition of Massachusetts-based Nexcelom Bioscience.
Thermo Fisher Scientific Inc. is acquiring contract researcher PPD Inc. for $17.4 billion as the medical device maker adds more muscle to the company’s pharmaceutical services business.